Oculis Holding AG
Privosegtor (OCS-05)
optic neuritis
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Privosegtor (OCS-05) for optic neuritis around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“the FDA granting Privosegtor Breakthrough Therapy designation for the treatment of optic neuritis”